Regeneron Pharmaceuticals (REGN) stock
NASDAQ
As of the Nov 5, 2026 close (U.S. Eastern)
Events and reference metrics · 1
- Market cap
- $98.3B
- As of Nov 5, 2026
- P/E
- 20.41x
- Trailing twelve months
- P/B
- 2.94x
- Latest reported equity
- P/S
- 5.82x
- Trailing twelve months
- ROE
- 14.4%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 5, 2026 and may differ from the current price.
- Market cap
- $98.3B
- As of Nov 5, 2026
- P/E
- 20.41x
- Trailing twelve months
- P/B
- 2.94x
- Latest reported equity
- P/S
- 5.82x
- Trailing twelve months
- ROE
- 14.4%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 5, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 5, 2026 · Financial period · Trailing twelve months
P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock
P/E
20.41x
P/B
2.94x
P/S
5.82x
Earnings and dividend metrics▾
Earnings
EPS
$51.24
Earnings per share
BPS
$356.37
Book value per share
ROE
14.4%
Return on equity
- EPS — what one share earned over the last four quarters. This company earned $51.24 per share.
- BPS — net assets divided by the number of shares. Each share is backed by $356.37 of net assets.
- ROE — how much the company earned on shareholder equity over a year: 14.4%.
Dividends
Dividend per share
$3.94
Payout ratio
7.7%
Dividend per share and payout ratio are for fiscal 2025.
- Dividend per share — the fiscal-year dividend per share. For one hundred shares that is about $394.00 before tax.
- Payout ratio — 7.7% of earnings was paid out as dividends.
Reference only · not a promise of future dividends
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from SEC financial filings: net income and revenue are summed over the latest four quarters, and equity is the latest reported balance.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Latest earnings
SEC filingsJul–Sep 2026(FY2026 Q3)
Revenue increased 36.3% from the same period a year earlier.
Key reported figures come first. Select one to see the same quarter across three years.
Revenue · same quarter, three years
Year-ago quarter $3.75B+36.3%
$3.72B
Jul–Sep '24
$3.75B
Jul–Sep '25
$5.12B
Jul–Sep '26
The next earnings date has not been confirmed yet.
ⓘ Notes on these figures▾
- Results for Jul–Sep 2026 are from the 10-Q submitted to SEC EDGAR on Oct 30, 2026.
- Earnings per share increased 35.5% from the same quarter a year earlier.
- Revenue increased 36.3% from the same quarter a year earlier.
- Operating income increased 99.4% from the same quarter a year earlier.
- Net income increased 33.5% from the same quarter a year earlier.
Filed Oct 30, 2026 · 10-Q · SEC EDGAR · View original
Reported results are from SEC EDGAR filings. Reference information only, not investment advice.
Insider transactions
Recent Form 4 filings grouped by person, date and transaction type.
- Zoghbi Huda YDirector · Nov 3, 2026Open-market sale7,439 shares · $7.2MAvg. price $970.463
Show 2 price lots
- 6,939 shares × $970.42$6.7M
- 500 shares × $971.06$486K
- Zoghbi Huda YDirector · Nov 3, 2026Option exercise7,439 shares · $2.8MAvg. price $380.959,142 shares held after
- MURPHY ANDREW JCo-Chief Scientific Officer · Nov 3, 2026Gift1,054 shares · $0Avg. price $046,779 shares held after
- SING GEORGE LDirector · Nov 2, 2026Open-market sale21,129 shares · $20.4MAvg. price $964.3787
Show 9 price lots
- 7,073 shares × $965.38$6.8M
- 4,338 shares × $963.47$4.2M
- 2,670 shares × $964.57$2.6M
- 2,522 shares × $962.61$2.4M
- 1,522 shares × $966.27$1.5M
- 1,224 shares × $960.57$1.2M
- 1,040 shares × $967.07$1.0M
- 540 shares × $961.85$519K
- 200 shares × $970.18$194K
- LAROSA JOSEPH JEVP General Counsel and Secret · Nov 2, 2026Open-market sale4,466 shares · $4.3MAvg. price $965.4926
Show 2 price lots
- 3,939 shares × $965.41$3.8M
- 527 shares × $966.11$509K
- POON CHRISTINE ADirector · Nov 2, 2026Open-market sale7,830 shares · $7.6MAvg. price $969.0878
Show 6 price lots
- 3,203 shares × $969.5$3.1M
- 2,499 shares × $968.58$2.4M
- 937 shares × $970.51$909K
- 772 shares × $967.38$747K
- 218 shares × $966.74$211K
- 201 shares × $971.31$195K
- LAROSA JOSEPH JEVP General Counsel and Secret · Nov 2, 2026Shares withheld for taxes8,686 shares · $8.3MAvg. price $950.543,372 shares held after
- LAROSA JOSEPH JEVP General Counsel and Secret · Nov 2, 2026Option exercise12,283 shares · $4.7MAvg. price $381.9252,058 shares held after
- Fenimore Christopher R.EVP Finance CFO · Nov 2, 2026Shares withheld for taxes4,243 shares · $4.0MAvg. price $950.521,741 shares held after
- SING GEORGE LDirector · Nov 2, 2026Option exercise15,269 shares · $5.8MAvg. price $378.7655
Show 2 price lots
- 7,830 shares × $376.69$2.9M
- 7,439 shares × $380.95$2.8M
- POON CHRISTINE ADirector · Nov 2, 2026Option exercise7,830 shares · $2.9MAvg. price $376.6913,049 shares held after
- Fenimore Christopher R.EVP Finance CFO · Nov 2, 2026Option exercise6,000 shares · $2.3MAvg. price $381.9225,984 shares held after
- Fenimore Christopher R.EVP Finance CFO · Nov 2, 2026Gift15 shares · $0Avg. price $021,726 shares held after
- BROWN MICHAEL SDirector · Oct 30, 2026Open-market sale1,929 shares · $1.7MAvg. price $8751,380 shares held after
- McCourt MarionEVP Commercial · Oct 30, 2026Open-market sale1,132 shares · $984KAvg. price $869.4310,871 shares held after
- Guarini KathrynDirector · Oct 30, 2026Open-market sale400 shares · $360KAvg. price $900603 shares held after
- BROWN MICHAEL SDirector · Oct 30, 2026Option exercise1,929 shares · $1.4MAvg. price $725.893,309 shares held after
- Guarini KathrynDirector · Oct 30, 2026Option exercise400 shares · $288KAvg. price $719.371,003 shares held after
- MURPHY ANDREW JCo-Chief Scientific Officer · Oct 14, 2026Open-market sale2,235 shares · $1.7MAvg. price $776.2631
Show 6 price lots
- 463 shares × $780.63$361K
- 454 shares × $778.64$354K
- 380 shares × $779.59$296K
- 376 shares × $775.46$292K
- 283 shares × $771.56$218K
- 279 shares × $766.47$214K
Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.
Recent SEC filings
40 filingsRecent filing summaries
Newest first by publication date · may differ from the filing date
- AI summary8-KRegeneron said Sanofi will make an upfront payment of $1.0 billion to it under the Sixth Amendment, and that it will be entitled to receive up to an additional $7.0 billion in aggregate milestone payments tied to the New Licensed Products.Published Oct 6, 2026 · Filed Oct 6, 2026Read the summary →
- AI summary8-KRegeneron said that at its June 12, 2026 Annual Meeting of Shareholders, 5 Class II director nominees were elected to serve until the 2027 Annual Meeting of Shareholders. The nominees were Joseph L. Goldstein, Christine A. Poon, David P. Schenkein, Craig B. Thompson and Huda Y. Zoghbi.Published Sep 30, 2026 · Filed Jun 17, 2026Read the summary →
- AI summary8-KThe company said its total revenues for Q4 2025 were $3,884 million, up 3% from a year earlier, and its full-year total revenues were $14,343 million, up 1%. GAAP net income for Q4 was $845 million, down 8%, and full-year GAAP net income was $4,505 million, up 2%.Published Oct 2, 2026 · Filed Jan 30, 2026Read the summary →
Filings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.
Company overview
Expand ▾
Regeneron Pharmaceuticals (REGN) stock information
NASDAQ
Regeneron Pharmaceuticals (REGN) is listed on NASDAQ. Its market capitalization is about $98.3B. On trailing-twelve-month earnings the P/E ratio is 20.41, and the P/B ratio is 2.94. Return on equity is 14.4%. These figures are computed in-house from official filings and are reference information only.
Regeneron Pharmaceuticals — frequently asked questions
- What is the P/E ratio of Regeneron Pharmaceuticals (REGN)?
- On a trailing-twelve-month basis, REGN trades at a P/E ratio of 20.41. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of Regeneron Pharmaceuticals?
- REGN has a market capitalization of about $98.3B. The figure moves with the share price and is refreshed each trading day.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.